RISING PHARMA HOLDINGS, INC. — Escitalopram Importer Profile
Pharmaceutical Importer · #7 buyer for Escitalopram · $3.5M import value · 194 shipments · UNITED STATES · DGFT Verified
RISING PHARMA HOLDINGS, INC. is the #7 importer of Escitalopram from India with $3.5M in import value and 194 verified shipments. RISING PHARMA HOLDINGS, INC. holds a 1.6% market share in Escitalopram imports based in UNITED STATES. The company sources from 2 verified suppliers across 126 formulations shipped to 1 country. Overall, RISING PHARMA HOLDINGS, INC. imports 18 pharmaceutical products worth $87.0M across 11 therapeutic categories.
RISING PHARMA HOLDINGS, INC. — Escitalopram Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Escitalopram to RISING PHARMA HOLDINGS, INC.?
Verified from 194 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| GRAVITI PHARMACEUTICALS PRIVATE LIMITED | $3.5M | 190 | 98.2% |
| AUROBINDO PHARMA LIMITED | $63.1K | 4 | 1.8% |
RISING PHARMA HOLDINGS, INC. sources Escitalopram from 2 verified Indian suppliers based on 194 customs records. The primary supplier is GRAVITI PHARMACEUTICALS PRIVATE LIMITED accounting for 98.2% of imports.
How Does RISING PHARMA HOLDINGS, INC. Compare to Nearest Escitalopram Importers?
Buyers ranked immediately above and below #7 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | LEK S.A. | POLAND | $4.1M | 112 | $36.5K |
| 1 | CIPLA MAROC | MOROCCO | $3.5M | 71 | $50.0K |
| 7 | RISING PHARMA HOLDINGS, INC. ★ | UNITED STATES | $3.1M | 174 | $18.0K |
| 3 | AUROLOGISTICS LLC (AUROBINDO PHARMA | UNITED STATES | $2.9M | 57 | $50.0K |
| 11 | YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $2.1M | 93 | $22.5K |
RISING PHARMA HOLDINGS, INC. ranks #7 among 628 Escitalopram importers from India. Average shipment value of $18.0K compared to the market average of $53.1K. The closest competitors by value are LEK S.A. and CIPLA MAROC.
Where Does RISING PHARMA HOLDINGS, INC. Import Escitalopram To?
Destination countries from 194 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $3.5M | 194 | 100.0% |
RISING PHARMA HOLDINGS, INC. imports Escitalopram to 1 country. The primary destination is UNITED STATES receiving 100.0% of shipments worth $3.5M.
What Escitalopram Formulations Does RISING PHARMA HOLDINGS, INC. Import?
| Formulation | Value | Shipments |
|---|---|---|
| ESCITALOPRAM TABLETS USP 10MG (29888X100'S) (BATCH NOS: ECB125004D) | $41.1K | 1 |
| ESCITALOPRAM TABLETS USP 10MG (29760X100'S)(BATCH NOS: ECB125005D) | $40.9K | 1 |
| ESCITALOPRAM TABLETS USP 10 MG (29504X100'S) (BATCH NOS: ECB125006D) | $40.5K | 1 |
| ESCITALOPRAM TABLETS USP 10 MG (29440X100'S) (BATCH NOS: ECB225007D) | $40.5K | 1 |
| ESCITALOPRAM TABLETS USP 10MG (29120X100'S)(BATCH NOS: ECB125009D) | $40.1K | 1 |
| ESCITALOPRAM TABLETS USP 10MG (28416X100'S)(BATCH NOS: ECB125003D) | $39.0K | 1 |
| ESCITALOPRAM TABLETS USP 10MG (3060X1000S)(BATCH NO.ECB124039G) | $35.2K | 3 |
| ESCITALOPRAM TABLETS USP 10MG (3049X1000S)(BATCH NO.ECB124040G) | $35.0K | 3 |
| ESCITALOPRAM TABLETS USP 10MG (3038X1000S)(BATCH NO.ECB124038G) | $34.9K | 3 |
| ESCITALOPRAM TABLETS USP 10MG (3034X1000'S)(BATCH NO: ECB124066G) | $34.9K | 3 |
RISING PHARMA HOLDINGS, INC. imports 126 distinct Escitalopram formulations from India. The top formulation is ESCITALOPRAM TABLETS USP 10MG (29888X100'S) (BATCH NOS: ECB1 with 1 shipments worth $41.1K.
Regulatory Requirements: Importing Escitalopram into United States
What RISING PHARMA HOLDINGS, INC. and other importers must comply with to import Escitalopram from India
Regulatory Authority
U.S. Food and Drug Administration (FDA)
Approval Process for Generic Escitalopram
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10–18 months for ANDA approval
GMP Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
Import Licence & Documentation
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
Labeling & Packaging
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Escitalopram from India and How Much Does RISING PHARMA HOLDINGS, INC. Import?
India exported $33.3M worth of Escitalopram through 5,457 shipments from 231 suppliers to 95 countries, serving 628 buyers globally. RISING PHARMA HOLDINGS, INC. imports $3.5M of this total, accounting for 1.6% of India's Escitalopram exports with 194 shipments from UNITED STATES. This is verified from 194 customs shipment records covering 126 distinct formulations.
What Is the Average Order Value for RISING PHARMA HOLDINGS, INC.'s Escitalopram Imports?
RISING PHARMA HOLDINGS, INC.'s average Escitalopram order value is $18.2K per consignment, based on 194 shipments totaling $3.5M. RISING PHARMA HOLDINGS, INC. is based in UNITED STATES and ranks #7 among all Escitalopram importers from India by value. The company sources from 2 verified suppliers in India.
Who Supplies Escitalopram to RISING PHARMA HOLDINGS, INC.?
RISING PHARMA HOLDINGS, INC. sources Escitalopram from 2 verified Indian suppliers: GRAVITI PHARMACEUTICALS PRIVATE LIMITED ($3.5M, 98.2%), AUROBINDO PHARMA LIMITED ($63.1K, 1.8%). This is based on 194 customs records.
How Does RISING PHARMA HOLDINGS, INC. Compare to Other Escitalopram Importers?
RISING PHARMA HOLDINGS, INC. ranks #7 among 628 Escitalopram importers from India with a 1.6% market share. The top 3 importers are TORRENT PHARMA INC ($4.2M), LEK S.A. ($4.1M), CIPLA MAROC ($3.5M). RISING PHARMA HOLDINGS, INC. processed 194 shipments from UNITED STATES.
What Other CNS & Psychiatric Products Does RISING PHARMA HOLDINGS, INC. Import?
RISING PHARMA HOLDINGS, INC. also imports these cns & psychiatric products. Each links to the detailed product page.
About RISING PHARMA HOLDINGS, INC.
RISING PHARMA HOLDINGS, INC. imports 18 products worth $87.0M. Beyond Escitalopram, top products include Gabapentin, Furosemide, Ondansetron, Pioglitazone, Fluconazole. View the complete RISING PHARMA HOLDINGS, INC. profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Escitalopram — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Escitalopram shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: RISING PHARMA HOLDINGS, INC. matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as RISING PHARMA HOLDINGS, INC.'s capped import value divided by total capped export value for Escitalopram across all Indian exporters.
- 5.Verified Records: This page is backed by 194 individual customs records matching RISING PHARMA HOLDINGS, INC. importing Escitalopram, covering 126 formulations from 2 verified suppliers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 95+ countries, 628+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Escitalopram Import Data for RISING PHARMA HOLDINGS, INC.
Access order-level details, pricing data, supplier connections, and competitive analysis for RISING PHARMA HOLDINGS, INC.'s Escitalopram imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
RISING PHARMA HOLDINGS, INC.
Full Company Profile →
18 products · $87.0M total trade · 11 categories
RISING PHARMA HOLDINGS, INC. × Escitalopram
Verified from customs records
Company Overview
Top Products by RISING PHARMA HOLDINGS, INC.
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for RISING PHARMA HOLDINGS, INC..
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Escitalopram. For current order-level data, contact TransData Nexus.